BCL2 and gastric cancer: The Western blot results showed that CM-M2 was able to downregulate the expression of Caspase-3 in AGS and HGC-27 cancer cells, as well as reduce the ratio of Bax/Bcl-2 in the three gastric cancer cells, whereas the CM-DOP treatment significantly upregulated Caspase-3 and increased the ratio of Bax/Bcl-2.